Home › Blood Disorders › Washington › Seattle
Blood Disorders clinical trials in Seattle, WA
5 studies for Blood Disorders are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- University of Washingto, Seattle
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RecruitingPhase 3
- University of Washingto, Seattle
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
- Washington Center for Bleeding Disorders, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RecruitingPhase 2/3
- Seattle Cancer Care Alliance, Seattle
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
About Blood Disorders
Blood disorders affect one or more parts of the blood and prevent your blood from doing its job. Find out about the types, causes, and treatments.
More about Blood Disorders on MedlinePlus
Blood Disorders trials in other cities
- Boston, MA10 studies
- Atlanta, GA10 studies
- Los Angeles, CA9 studies
- Houston, TX9 studies
- The Bronx, NY8 studies
- New York City, NY7 studies
- Nashville, TN7 studies
- Mountain View, CA6 studies
- Portland, OR5 studies
- Durham, NC5 studies
- Greenville, NC5 studies
- Washington, DC5 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)50 studies
- Prostate Cancer44 studies
- Breast Cancer40 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer31 studies
- Multiple Myeloma22 studies
- Pancreatic Cancer22 studies
- Bladder Cancer21 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.